|
|
|
|
| LEADER |
01696nam a2200265 u 4500 |
| 001 |
EB002010745 |
| 003 |
EBX01000000000000001173644 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
220201 r ||| eng |
| 100 |
1 |
|
|a Assasi, Nazila
|
| 245 |
0 |
0 |
|a Posaconazole for the prophylaxis and treatment of invasive aspergillosis
|h Elektronische Ressource
|b a review of clinical effectiveness and guidelines
|c authors, Nazila Assasi, Aleksandra Grobelna
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c 2017, July 13, 2017
|
| 300 |
|
|
|a 1 PDF file (59 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 700 |
1 |
|
|a Grobelna, Aleksandra
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: peer reviewed summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK531397
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The purpose of this report is to review provide a synthesis of the best available evidence on the clinical effectiveness of posaconazole for the treatment and prophylaxis of invasive aspergillosis (IA) and to review and summarize recommendations from the related evidence-based guidelines. This report is an update of a previous CADTH Rapid Response report (2016), which found favourable evidence regarding the use of posaconazole for the treatment and prophylaxis of aspergillosis and candidiasis. However, the present review is exclusively focused on aspergillosis
|